DreaMed Diabetes, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DreaMed Diabetes, Ltd.
Reimagining The Patient Experience By Putting Practitioners At The Center
Keeping a strategic focus but pivoting to meet health care priorities on demand were qualities Align Technology’s EMEA managing director Markus Sebastian ensured were uppermost at the company during the COVID-19 pandemic.
DreaMed Receives Another FDA Clearance For AI-Powered Diabetes Software
Israeli firm DreaMed has scored a new US Food and Drug Administration clearance for its AI-based diabetes decision support system Advisor Pro. The clearance enables physicians to use the software for patients with type 1 diabetes using continuous glucose monitoring (CGMs) and blood glucose meters (BGMs).
2018 US Device Approvals: The Year Of De Novos And Digital Health
It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.
Medtronic’s Deal With Aetna Heralds New Value-Based Era
Medtronic's outcomes-based insulin pump supply deal with Aetna is the latest example of the medtech industry's shift toward value-based care.
- Drug Delivery
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.